May 14, 2020 / 1:08 AM / 12 days ago

BRIEF-Genscript Biotech Updates On Phase 1B/2 Cartitude-1 Study Evaluating JNJ-68284528

May 14 (Reuters) - Genscript Biotech Corp:

* UPDATES ON PHASE 1B/2 CARTITUDE-1 STUDY EVALUATING EFFICACY & SAFETY OF JNJ-68284528

* LONGER-TERM FOLLOW-UP RESULTS FROM PHASE 1B PORTION OF STUDY SHOW ALL PATIENTS RESPONDED TO TREATMENT

* LONGER-TERM FOLLOW-UP RESULTS FROM PHASE 1B PORTION SHOW RESPONSES WERE DEEP & DURABLE WITH 86% OF PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below